Origin
Financiado
Origin Development of a compact time efficient and safe medical diagnostic mac...
Current tissue processors on the market take up to 24 hours to process samples for diagnosis and leave the operator exposed to chemical fumes. They also use different kinds of chemicals, in large volumes, which leads to cross cont...
Current tissue processors on the market take up to 24 hours to process samples for diagnosis and leave the operator exposed to chemical fumes. They also use different kinds of chemicals, in large volumes, which leads to cross contamination of chemicals and samples. This results in more plastic packaging to dispose of, making the process both costly and environmental unfriendly. Our company, DIAPATH SpA, is developing an innovative solution to these problems - the E-Processor. DIAPATH has been in the tissue processing industry since 1997 and currently has a turnover of €12Million and 100 employees. The E-Processor reduces the number of processing steps, and reduces the number of chemicals used. The operator will be safeguarded from chemical fumes and chemical containers will now be disposed of in a safe and environmentally friendly way. Our value proposition is, less operating costs due to reduced chemicals and packaging, faster diagnosis and results for patients. Our target users are Hospitals and Diagnostics Laboratories. The current global diagnostics market is estimated at €243.59 Million and expected to reach €378 Million by year 2025. Our entry point for our innovation will be the European market, where we already have significant market share. We will be using our extensive distribution chain to bring our innovation to international markets. Our innovation is currently at prototype stage with a compact functional machine. Further validation and tests remain to be done to bring it to market. The purpose of the phase 1 is to carry out feasibility studies before commercialisation. This will allow us to come up with a detailed business plan covering a projected five-year period. This innovation will grow our market share from 30% and increase our turnover to €50million by 2023. It will also create 15 new jobs.
ver más
Duración del proyecto: 3 meses
Fecha Inicio: 2019-05-11
Fecha Fin: 2019-08-31
Fecha Fin: 2019-08-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2019-08-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
DIAPATH SPA
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
163.55K€ |
Participante